Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study Read more about Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More Read more about A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines Read more about The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC Read more about (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
Remote Assessment of Outpatient With Severe Acute Respiratory Syndrome (SARS-CoV-2) Read more about Remote Assessment of Outpatient With Severe Acute Respiratory Syndrome (SARS-CoV-2)
ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19) Read more about ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)
SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study Read more about SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study
Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort. Read more about Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites Read more about Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M Read more about To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
